What is the recommended staging workup and stage grouping for non‑small cell lung cancer (NSCLC)?

NSCLC Staging: Recommended Workup and Stage Grouping

All patients with suspected or confirmed NSCLC should undergo contrast-enhanced CT chest and upper abdomen followed by PET-CT for initial staging, with pathological confirmation of mediastinal lymph nodes when positive on imaging, using EBUS/EUS as the preferred first-line invasive technique 1, 2.

Initial Imaging Workup

The staging evaluation begins with high-resolution imaging to assess both locoregional and distant disease:

• CT chest and upper abdomen (contrast-enhanced) is mandatory for all patients 1
• PET or PET-CT should follow, ideally within 4 weeks before treatment initiation 1, 2
• The CT component of PET-CT must be of sufficient diagnostic quality—modern high-resolution scanners are essential, not just attenuation correction scans 2

TNM Classification System

Use the 8th edition TNM staging system (7th edition in older guidelines, but 8th is current standard) 3. This system distinguishes:

• Early stages (I/II): Candidates for surgical resection
• Stage IIIA: Potentially resectable with multimodality therapy
• Unresectable stage III: Requires definitive chemoradiotherapy
• Stage IV: Metastatic disease requiring systemic therapy

Key T-Stage Refinements

• T1a: ≤2 cm
• T1b: >2-3 cm
• T2a: >3-5 cm
• T2b: >5-7 cm
• T3: >7 cm or specific invasion patterns
• For part-solid tumors, measure only the solid/invasive component for T staging 1

Mediastinal Lymph Node Staging Algorithm

This is the most critical component affecting treatment decisions:

When Mediastinal Nodes Appear Negative on CT and PET:

Proceed directly to surgery for peripheral tumors <3 cm with no FDG uptake concerns 3, 4

Perform invasive staging if any of these high-risk features present 1, 4:

• Central tumor location (inner two-thirds of lung)
• Tumor >3 cm
• Hilar lymph node involvement (N1)
• Primary tumor lacks FDG uptake (false-negative risk)
• Adenocarcinoma with high FDG uptake

When Mediastinal Nodes Appear Positive on CT or PET:

Pathological confirmation is mandatory except in bulky disease 3:

1. First-line: EBUS and/or EUS-guided needle aspiration 3, 2, 4

   • Less invasive and less costly than mediastinoscopy
   • Requires experienced operators
   • High negative predictive value when thorough

2. If EBUS/EUS negative but clinical suspicion remains high: Mediastinoscopy 3, 1

   • Highest negative predictive value of all techniques
   • Video-assisted mediastinoscopy (VAMS) preferred for upper mediastinal nodes
   • VATS for aortopulmonary window nodes

3. For left upper lobe tumors: Assess aortopulmonary window (station 5/6) via Chamberlain procedure, VATS, or extended cervical mediastinoscopy if other stations negative 4

Critical Distinction: Discrete vs. Bulky Nodes

• Discrete nodes: Individual nodes measurable on CT—require tissue confirmation
• Bulky nodes: Matted together, vessels encircled—may proceed without biopsy given high positive predictive value 3

Brain Imaging for Stage III Disease

All patients planned for curative treatment of stage III NSCLC should undergo brain imaging 1, 2:

• Preferred: Contrast-enhanced brain MRI 1, 2
• Alternative: Dedicated contrast-enhanced brain CT if MRI contraindicated 1, 2

There is controversy for earlier stages—NCCN recommends for all except stage IA, while ACCP restricts to stage III/IV and symptomatic patients 1. Given the high stakes of missing brain metastases in potentially curable disease, brain imaging should be strongly considered for all patients being evaluated for curative-intent therapy 1.

Distant Metastasis Evaluation

The initial CT chest/upper abdomen and PET-CT typically identify most distant metastases. Any single PET-positive distant lesion requires pathological confirmation before declaring stage IV disease 1.

Common Pitfalls to Avoid

1. Relying on PET-CT alone for mediastinal staging: PET has high negative predictive value but moderate positive predictive value—false positives from inflammation are common 2

2. Skipping invasive staging in high-risk scenarios: Even with negative PET, central tumors, N1 disease, and tumors >3 cm have significant occult N2 rates 1

3. Using low-quality CT from PET-CT scanner: The CT component must be diagnostic quality for accurate anatomic assessment 2

4. Inadequate sampling during invasive procedures: Thoroughness matters more than technique choice—systematic nodal station sampling is essential 4

5. Misclassifying multiple lung nodules: Distinguish true intrapulmonary metastases (same histology) from separate primary tumors—each requires different staging approach 1

Stage-Specific Workup Summary

Stage I/II (Early):

• CT chest/abdomen + PET-CT
• Invasive mediastinal staging only if high-risk features present
• Brain imaging: controversial, consider for stage IB and higher

Stage III (Locally Advanced):

• CT chest/abdomen + PET-CT (mandatory)
• Pathological mediastinal staging for all PET-positive nodes
• Brain MRI (mandatory for curative-intent treatment)
• Cardiopulmonary function testing if surgery or definitive RT planned

Stage IV (Metastatic):

• CT chest/abdomen + PET-CT
• Biopsy confirmation of single distant lesions
• Brain imaging
• Molecular testing for driver mutations (separate guideline topic)

This algorithmic approach ensures accurate staging while avoiding both under-staging (missing occult disease) and over-staging (false-positive findings), which directly impact survival through appropriate treatment selection 3, 2.